The majority of the analyst ratings for Cytokinetics are bullish or somewhat bullish, indicating a positive outlook for the stock. The average 12-month price target has also increased by 0.92% over the past month, suggesting that analysts are becoming more optimistic about the stock's performance. This is likely to have a positive short-term impact on CYTK's stock price.